Wells Fargo
ACTU

Wells Fargo’s Actuate Therapeutics ACTU Stock Holding History

Wells Fargo’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.74K Sell
2,446
-3,443
-58% -$7.98K ﹤0.01% 6279
2026
Q1 		$16.1K Sell
5,889
-14,257
-71% -$59.1K ﹤0.01% 5847
2025
Q4 		$123K Buy
20,146
+6,604
+49% +$45.4K ﹤0.01% 5299
2025
Q3 		$90.6K Buy
13,542
+746
+6% +$5.41K ﹤0.01% 5370
2025
Q2 		$78.2K Buy
+12,796
New +$112K ﹤0.01% 5334
2024
Q4 		– Sell
-3,392
Closed -$25.3K – 7234
2024
Q3 		$25.3K Buy
+3,392
New +$26.9K ﹤0.01% 5572

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $306M AUM 15.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

Wells Fargo's ACTU Position: Q2 2026 in Review

Wells Fargo reduced its Actuate Therapeutics (ACTU) stake by 58% in Q2 2026, selling an estimated $7.98K and leaving 2,446 shares worth $3.74K. The position accounts for ﹤0.01% of the portfolio, ranked #6279.

Wells Fargo first reported a position in ACTU in Q3 2024 and has held it in 6 quarters since. The position peaked at $123K in Q4 2025. 63 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Wells Fargo held 2,446 shares of Actuate Therapeutics worth $3.74K as of Q2 2026.
  • Wells Fargo sold 3,443 Actuate Therapeutics shares in Q2 2026, an estimated $7.98K.
  • Actuate Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6279 holding.
  • Wells Fargo first reported a position in Actuate Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • Wells Fargo's Actuate Therapeutics position peaked at $123K in Q4 2025.
  • 63 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.